TG Therapeutics Completes Enrollment in Phase 3 BRIUMVI Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy TGTX?
Source: Newsfilter
- Phase 3 Enrollment Completed: TG Therapeutics announced the completion of enrollment in its Phase 3 trial for BRIUMVI targeting relapsing multiple sclerosis, with topline data expected by late 2026 or early 2027, marking a significant milestone in the company's development program that could enhance its market competitiveness.
- Innovative Dosing Regimens: The trial evaluates subcutaneous BRIUMVI dosing every 8 weeks and 12 weeks, offering greater flexibility compared to the current biannual intravenous administration, which may attract more patients opting for self-managed treatment, thereby expanding the patient base.
- Safety Monitoring: In clinical trials, the incidence of infusion reactions for BRIUMVI was reported at 48%, with 0.6% of patients experiencing serious reactions, indicating the need for enhanced safety monitoring as the new administration method is promoted to mitigate potential risks.
- Broad Market Potential: As a novel monoclonal antibody targeting CD20-expressing B cells, BRIUMVI is expected to provide new treatment options for relapsing multiple sclerosis, with the global prevalence of MS on the rise, suggesting sustained market demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TGTX
Wall Street analysts forecast TGTX stock price to rise
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 34.600
Low
15.00
Averages
43.50
High
60.00
Current: 34.600
Low
15.00
Averages
43.50
High
60.00
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TG Therapeutics Completes Enrollment in Phase 3 Trial for BRIUMVI
- Phase 3 Trial Enrollment Complete: TG Therapeutics announced the completion of enrollment in its Phase 3 trial for BRIUMVI, aimed at providing new treatment options for over 1 million MS patients in the U.S., significantly enhancing the company's market position in biotechnology.
- Drug Characteristics and Approval: BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, approved by the FDA for one-hour intravenous infusion in adults, demonstrating its efficacy in treating relapsing forms of multiple sclerosis.
- Trial Design and Objectives: The Phase 3 trial is a non-inferiority, randomized, open-label multicenter study comparing subcutaneous dosing regimens every 8 and 12 weeks against the approved IV schedule, primarily assessing non-inferior pharmacokinetic exposure at week 24 to offer patients more flexible administration options.
- Future Outlook and Market Reaction: The CEO indicated that subcutaneous BRIUMVI is expected to share topline data around late 2026 or early 2027, with the market responding positively to the news, although the stock saw a slight decline in after-hours trading, reflecting investor interest in future potential.
See More
TG Therapeutics Completes Enrollment in Phase 3 BRIUMVI Trial
- Phase 3 Enrollment Completed: TG Therapeutics announced the completion of enrollment in its Phase 3 trial for BRIUMVI targeting relapsing multiple sclerosis, with topline data expected by late 2026 or early 2027, marking a significant milestone in the company's development program that could enhance its market competitiveness.
- Innovative Dosing Regimens: The trial evaluates subcutaneous BRIUMVI dosing every 8 weeks and 12 weeks, offering greater flexibility compared to the current biannual intravenous administration, which may attract more patients opting for self-managed treatment, thereby expanding the patient base.
- Safety Monitoring: In clinical trials, the incidence of infusion reactions for BRIUMVI was reported at 48%, with 0.6% of patients experiencing serious reactions, indicating the need for enhanced safety monitoring as the new administration method is promoted to mitigate potential risks.
- Broad Market Potential: As a novel monoclonal antibody targeting CD20-expressing B cells, BRIUMVI is expected to provide new treatment options for relapsing multiple sclerosis, with the global prevalence of MS on the rise, suggesting sustained market demand.
See More
Analysis of XBI ETF Trading Dynamics
- Price Range Fluctuation: The XBI ETF has a 52-week low of $66.66 and a high of $132.09, with the current trading price at $127.30, indicating significant volatility over the past year that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper market trend insights, aiding in the formulation of more effective trading strategies to enhance investment returns.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, offering flexibility that makes ETFs an effective tool for portfolio management.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps track notable inflows (new units created) or outflows (old units destroyed), which directly impacts the underlying holdings of the ETF and consequently affects overall market performance.
See More
Analysis of XBI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XBI ETF's 52-week low is $66.66 per share, with a high of $132.09, and a recent trading price of $119.75, indicating stability within its volatility range that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on significant inflows (new units created) or outflows (old units destroyed), which will affect the underlying holdings of the ETF and influence market dynamics.
See More
TG Therapeutics Secures $750 Million Credit Facility
- Expanded Financing: TG Therapeutics announced a new five-year $750 million senior secured credit facility managed by Blue Owl Capital, expected to provide $500 million in non-dilutive capital, enhancing financial flexibility to support future R&D initiatives.
- Debt Repayment Strategy: The new credit facility will be utilized to repay the existing $250 million senior secured credit, ensuring the company can reduce its financial burden while leveraging additional funds for strategic investments and operational expansion.
- Increased Share Repurchase Program: The company has been authorized to increase its share repurchase program from $100 million to $300 million, demonstrating confidence in its stock value and helping to enhance shareholder returns while boosting market expectations for future growth.
- Positive Market Reaction: Following the financing announcement, TG Therapeutics shares rose 1.70% in pre-market trading on Nasdaq to $30.55 per share, reflecting investor optimism regarding the company's financial health and strategic direction.
See More
TG Therapeutics Secures $750M Credit Facility
- Expanded Financing: TG Therapeutics has entered into a new five-year, $750 million senior secured credit facility with Blue Owl Capital, successfully repaying its previous $250 million credit facility, resulting in a net capital raise of $500 million that significantly strengthens the company's capital structure.
- Increased Capital Flexibility: The new credit agreement allows TG to access up to an additional $250 million of incremental capital at mutual discretion, raising the total facility size to $1 billion, thereby providing greater flexibility for future strategic investments.
- Stock Buyback Program Expansion: The company's board has authorized an increase in its stock repurchase program from $100 million to $300 million, reflecting confidence in the company's future performance while also creating additional value for shareholders.
- Buyback Progress: As of March 18, 2026, TG has repurchased approximately $38 million of common stock under the existing buyback program at an average price of $28.98 per share, indicating proactive measures in capital management.
See More
TG Therapeutics Completes Enrollment in Phase 3 Trial for BRIUMVI
- Phase 3 Trial Enrollment Complete: TG Therapeutics announced the completion of enrollment in its Phase 3 trial for BRIUMVI, aimed at providing new treatment options for over 1 million MS patients in the U.S., significantly enhancing the company's market position in biotechnology.
- Drug Characteristics and Approval: BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, approved by the FDA for one-hour intravenous infusion in adults, demonstrating its efficacy in treating relapsing forms of multiple sclerosis.
- Trial Design and Objectives: The Phase 3 trial is a non-inferiority, randomized, open-label multicenter study comparing subcutaneous dosing regimens every 8 and 12 weeks against the approved IV schedule, primarily assessing non-inferior pharmacokinetic exposure at week 24 to offer patients more flexible administration options.
- Future Outlook and Market Reaction: The CEO indicated that subcutaneous BRIUMVI is expected to share topline data around late 2026 or early 2027, with the market responding positively to the news, although the stock saw a slight decline in after-hours trading, reflecting investor interest in future potential.
See More
TG Therapeutics Completes Enrollment in Phase 3 BRIUMVI Trial
- Phase 3 Enrollment Completed: TG Therapeutics announced the completion of enrollment in its Phase 3 trial for BRIUMVI targeting relapsing multiple sclerosis, with topline data expected by late 2026 or early 2027, marking a significant milestone in the company's development program that could enhance its market competitiveness.
- Innovative Dosing Regimens: The trial evaluates subcutaneous BRIUMVI dosing every 8 weeks and 12 weeks, offering greater flexibility compared to the current biannual intravenous administration, which may attract more patients opting for self-managed treatment, thereby expanding the patient base.
- Safety Monitoring: In clinical trials, the incidence of infusion reactions for BRIUMVI was reported at 48%, with 0.6% of patients experiencing serious reactions, indicating the need for enhanced safety monitoring as the new administration method is promoted to mitigate potential risks.
- Broad Market Potential: As a novel monoclonal antibody targeting CD20-expressing B cells, BRIUMVI is expected to provide new treatment options for relapsing multiple sclerosis, with the global prevalence of MS on the rise, suggesting sustained market demand.
See More
Analysis of XBI ETF Trading Dynamics
- Price Range Fluctuation: The XBI ETF has a 52-week low of $66.66 and a high of $132.09, with the current trading price at $127.30, indicating significant volatility over the past year that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper market trend insights, aiding in the formulation of more effective trading strategies to enhance investment returns.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, offering flexibility that makes ETFs an effective tool for portfolio management.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps track notable inflows (new units created) or outflows (old units destroyed), which directly impacts the underlying holdings of the ETF and consequently affects overall market performance.
See More
Analysis of XBI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XBI ETF's 52-week low is $66.66 per share, with a high of $132.09, and a recent trading price of $119.75, indicating stability within its volatility range that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on significant inflows (new units created) or outflows (old units destroyed), which will affect the underlying holdings of the ETF and influence market dynamics.
See More
TG Therapeutics Secures $750 Million Credit Facility
- Expanded Financing: TG Therapeutics announced a new five-year $750 million senior secured credit facility managed by Blue Owl Capital, expected to provide $500 million in non-dilutive capital, enhancing financial flexibility to support future R&D initiatives.
- Debt Repayment Strategy: The new credit facility will be utilized to repay the existing $250 million senior secured credit, ensuring the company can reduce its financial burden while leveraging additional funds for strategic investments and operational expansion.
- Increased Share Repurchase Program: The company has been authorized to increase its share repurchase program from $100 million to $300 million, demonstrating confidence in its stock value and helping to enhance shareholder returns while boosting market expectations for future growth.
- Positive Market Reaction: Following the financing announcement, TG Therapeutics shares rose 1.70% in pre-market trading on Nasdaq to $30.55 per share, reflecting investor optimism regarding the company's financial health and strategic direction.
See More
TG Therapeutics Secures $750M Credit Facility
- Expanded Financing: TG Therapeutics has entered into a new five-year, $750 million senior secured credit facility with Blue Owl Capital, successfully repaying its previous $250 million credit facility, resulting in a net capital raise of $500 million that significantly strengthens the company's capital structure.
- Increased Capital Flexibility: The new credit agreement allows TG to access up to an additional $250 million of incremental capital at mutual discretion, raising the total facility size to $1 billion, thereby providing greater flexibility for future strategic investments.
- Stock Buyback Program Expansion: The company's board has authorized an increase in its stock repurchase program from $100 million to $300 million, reflecting confidence in the company's future performance while also creating additional value for shareholders.
- Buyback Progress: As of March 18, 2026, TG has repurchased approximately $38 million of common stock under the existing buyback program at an average price of $28.98 per share, indicating proactive measures in capital management.
See More
